Ascendis Pharma A/S $ASND
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-34
RECRUITING3
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Palopegteriparatide NCT07706764 |
P3 | Recruiting | Hypoparathyroidism | 12 | 2027-08 |
| teACH NCT06732895 |
P2 | Active, not recruiting | Achondroplasia | 25 | 2027-09 (+9 mo) |
| Navepegritide NCT06079398 |
P2 | Recruiting | Achondroplasia | 72 | 2027-12 (+21 mo) |
| Lonapegsomatropin [SKYTROFA®] NCT07221851 |
P3 | Recruiting | Turner Syndrome; Short Stature Homeobox Gene Mutation | 186 | 2028-02 |
| cAtCH NCT07924059 |
P3 | Not yet recruiting | Achondroplasia | 144 | 2028-09 |
| HCH UpliftMono NCT07917143 |
P3 | Not yet recruiting | Hypochondroplasia | 81 | 2028-10 |